First Trust Advisors LP Has $3.23 Million Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

First Trust Advisors LP lifted its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating) by 116.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 277,274 shares of the biotechnology company’s stock after purchasing an additional 149,167 shares during the quarter. First Trust Advisors LP owned approximately 0.17% of Ironwood Pharmaceuticals worth $3,233,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. ProShare Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 3.2% during the fourth quarter. ProShare Advisors LLC now owns 55,111 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 1,692 shares during the last quarter. Zeke Capital Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 9.0% during the third quarter. Zeke Capital Advisors LLC now owns 21,003 shares of the biotechnology company’s stock worth $274,000 after acquiring an additional 1,740 shares during the last quarter. First Quadrant L P CA grew its stake in shares of Ironwood Pharmaceuticals by 5.7% during the fourth quarter. First Quadrant L P CA now owns 50,100 shares of the biotechnology company’s stock worth $584,000 after purchasing an additional 2,700 shares during the period. Swiss National Bank grew its stake in shares of Ironwood Pharmaceuticals by 0.9% during the third quarter. Swiss National Bank now owns 340,000 shares of the biotechnology company’s stock worth $4,440,000 after purchasing an additional 2,900 shares during the period. Finally, Wedge Capital Management L L P NC grew its stake in shares of Ironwood Pharmaceuticals by 20.9% during the fourth quarter. Wedge Capital Management L L P NC now owns 18,383 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 3,182 shares during the period.

NASDAQ:IRWD opened at $11.59 on Friday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $10.13 and a 1 year high of $14.27. The company has a current ratio of 4.61, a quick ratio of 4.61 and a debt-to-equity ratio of 0.56. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of 3.63 and a beta of 1.17. The stock has a 50-day moving average price of $12.17 and a two-hundred day moving average price of $11.72.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.10). Ironwood Pharmaceuticals had a net margin of 124.83% and a return on equity of 33.93%. The business had revenue of $97.53 million during the quarter, compared to analyst estimates of $96.62 million. During the same period in the previous year, the firm posted $0.24 earnings per share. The firm’s revenue was up 9.8% on a year-over-year basis. Sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.28 earnings per share for the current year.

IRWD has been the subject of a number of analyst reports. Piper Sandler initiated coverage on Ironwood Pharmaceuticals in a research note on Friday, April 22nd. They set an “overweight” rating and a $16.00 price objective for the company. TheStreet raised Ironwood Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, January 19th. Finally, StockNews.com cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 26th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $14.75.

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 3,031 shares of the business’s stock in a transaction dated Thursday, March 24th. The stock was sold at an average price of $12.75, for a total value of $38,645.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.60% of the stock is currently owned by insiders.

Ironwood Pharmaceuticals Profile (Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Featured Stories

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.